Human pluripotent stem cells (hPSCs) represent a promising source of patient-specific cells for disease modeling, drug screens, and cellular therapies. However, the inability to derive engraftable human hematopoietic stem and progenitor cells (HSPCs) has limited their characterization to in vitro assays. We report a strategy to respecify lineage-restricted CD34 + CD45 + myeloid precursors derived from hPSCs into multilineage progenitors that can be expanded in vitro and engrafted in vivo. HOXA9, ERG, and RORA conferred self-renewal and multilineage potential in vitro and maintained primitive CD34 + CD38 À cells. Screening cells via transplantation revealed that two additional factors, SOX4 and MYB, conferred engraftment. Progenitors specified with all five factors gave rise to reproducible shortterm engraftment with myeloid and erythroid lineages. Erythroid precursors underwent hemoglobin switching in vivo, silencing embryonic and activating adult globin expression. Our combinatorial screening approach establishes a strategy for obtaining transcription-factor-mediated engraftment of blood progenitors from human pluripotent cells.
SUMMARY
Human pluripotent stem cells (hPSCs) represent a promising source of patient-specific cells for disease modeling, drug screens, and cellular therapies. However, the inability to derive engraftable human hematopoietic stem and progenitor cells (HSPCs) has limited their characterization to in vitro assays. We report a strategy to respecify lineage-restricted CD34 + CD45 + myeloid precursors derived from hPSCs into multilineage progenitors that can be expanded in vitro and engrafted in vivo. HOXA9, ERG, and RORA conferred self-renewal and multilineage potential in vitro and maintained primitive CD34 + CD38 À cells. Screening cells via transplantation revealed that two additional factors, SOX4 and MYB, conferred engraftment. Progenitors specified with all five factors gave rise to reproducible shortterm engraftment with myeloid and erythroid lineages. Erythroid precursors underwent hemoglobin switching in vivo, silencing embryonic and activating adult globin expression. Our combinatorial screening approach establishes a strategy for obtaining transcription-factor-mediated engraftment of blood progenitors from human pluripotent cells.
INTRODUCTION
Recent advances in reprogramming to induced pluripotent stem cells (IPSCs) have provided access to a wide array of patientspecific pluripotent lines that have the potential to give rise to any somatic cell type. A large number of pluripotent lines have been generated from patients with hematologic diseases, including Fanconi anemia (Mü ller et al., 2012) , sickle cell anemia (Zou et al., 2011) , Diamond Blackfan anemia (Garç on et al., 2013) , Shwachman Diamond syndrome (Tulpule et al., 2013) , chronic myelogenous leukemia (Kumano et al., 2012) , JAK2 V617F myelo-proliferative disorder (Ye et al., 2009 ), dyskeratosis congenita (Agarwal et al., 2010) , Pearson syndrome , and others. These lines have the potential to become powerful models to gain insight into the molecular basis of disease and platforms for drug screens (Cherry and Daley, 2013) . To reveal the disease phenotype, IPSCs have to be differentiated into the target cell type of interest-hematopoietic stem and progenitor cells (HSPCs). Numerous protocols for hematopoietic differentiation of hPSCs into short-lived progenitors and mature cells have been established (Chadwick et al., 2003; Kennedy et al., 2012) . However, no system presently exists to generate large numbers of transplantable cells from human pluripotent stem cells (hPSCs), thereby precluding disease modeling in vivo and hampering the scope of experiments and screens that can be performed.
A major hurdle for generating engraftable HSPCs is the complex nature of hematopoietic ontogeny. It is now widely accepted that hematopoietic cells arise during midgestation in multiple temporal waves from hemogenic endothelial (HE) cells lining the major arteries (Bertrand et al., 2010; Boisset et al., 2010) . Directed differentiation protocols attempt to recapitulate ontogeny by calibrated addition of morphogens such as BMP4, Activin A, and Notch ligands. These protocols can promote the emergence of HE cells and recapitulate the temporal waves of hematopoietic progenitors, but they generate few if any transplantable cells (Choi et al., 2012; Kennedy et al., 2012) . Prior reports of limited engraftment of hPSC-derived cells in immunodeficient mice have not been widely exploited owing to the heterogeneity among hPSC lines and variations among protocols (Ledran et al., 2008; Wang et al., 2005) . More importantly, these protocols generate only small numbers of transplantable cells, and without the possibility of expanding them, it is difficult to move toward more practical models, such as in vivo engraftment of disease IPSCs.
One approach that has not been extensively explored in hematopoietic development is transcription-factor-mediated specification and expansion of HSPCs. It was recently shown that a combination of Gata2, Gfi1b, Fos, and Etv6 promotes conversion of mouse fibroblasts into hematopoietic cells, suggesting that transcription factor reprogramming is a promising approach (Pereira et al., 2013) . However, since fibroblasts are a distinct cell type, the precise conversion to HSPCs remains a challenge. We propose that conversions from closely related lineages, which minimize the ''epigenetic distance'' to a desired cell type, provide a more favorable context for precise alterations in cell fate. One possible approach is to promote specification of HE into transplantable HSPCs, which takes advantage of normal developmental cues. However, the process of endothelial to hematopoietic transition remains poorly understood, making it difficult to design rational interventions. An alternative approach is to start with committed hematopoietic progenitors and revert them to a more immature state. Such ''respecification'' combines directed differentiation with transcription-based reprogramming to establish HSPC fate. A logical hypothesis is that the key regulatory factors that maintain HSCs can reactivate stem cell properties, such as self-renewal, in more mature progenitors. Molecular differences between primary human HSCs and progenitors have been well characterized by gene expression profiling, thereby enabling a rational approach to introduce candidate stem cell genes back into progenitors (Doulatov et al., 2010; Laurenti et al., 2013) .
Respecification was likely first demonstrated in mouse embryonic stem cells (ESCs) using the homeobox transcription factor HoxB4. Expression of HoxB4 in lineage-restricted hematopoietic progenitors isolated from embryoid body (EB) differentiation or from yolk sac endowed them with extended self-renewal and long-term multilineage engraftment capacity (Kyba et al., 2002) . HOXB4 has not functioned similarly in human ESCs (Lee et al., 2008; Wang et al., 2005) or HSCs (Amsellem et al., 2003) , suggesting species-specific differences. These studies, however, prompted us to search for factors tailored for hPSCs. Here, we identify HOX-and ETS-family transcription factors HOXA9 and ERG as inducers of self-renewal and multilineage potential in hematopoietic progenitors differentiated from hPSCs. The addition of SOX4 and MYB modulates this network to enable myeloid and erythroid engraftment, paving the way for in vivo models of hematological diseases from human IPSCs.
RESULTS

Selection of Candidate Transcription Factors
We hypothesized that introduction of stem cell transcription factors into hematopoietic progenitors derived from hPSCs would endow these cells with stem cell properties such as self-renewal potential. Gene expression of purified mouse and human HSCs has been extensively analyzed. Since functionally relevant factors are likely conserved, we used two independent mouse (Chambers et al., 2007; Ivanova et al., 2002) and two human (Doulatov et al., 2010; Novershtern et al., 2011 ) data sets to select transcriptional regulators more highly expressed in HSCs compared with progenitors or mature cells. Factors enriched in either of the two speciesspecific data sets were intersected to identify conserved regulators. These were then compared with gene sets differentially regulated during ontogeny to select factors upregulated in definitive HSCs (McKinney-Freeman et al., 2012) . From this list of 32 HSC-specific transcription factors, 9 are significantly underexpressed in CD34 + CD45 + EB progenitors compared with CD34 + CD38 À cord blood (CB) HSCs (Wang et al., 2005) .
These are ERG, KLF4, SOX4, MYB, RORA, HLF, HOXA5, HOXA9, and HOXA10 . These open reading frames were cloned into a pSMAL-GFP lentiviral vector. Lentiviruses were produced as a minilibrary of nine factors (9F), plus luciferase (LUC), which serves as an internal control ( Figure S1A available online).
An In Vitro Screen for Self-Renewal Capacity To generate hematopoietic progenitors, hPSCs were differentiated as EBs in the presence of BMP4 and cytokines, as previously described (Chadwick et al., 2003) . An ESC line, CHB6, and an IPSC line, MSC-IPS1, were selected based on their robust hemogenic potential ( Figure S1B ). In these conditions, CD34 + CD45 + progenitors appear at day 10 and expand until day 14 ( Figure 1A ). Since EBs in our protocol are cultured with serum, the day 14 progenitors likely represent a mixture of primitive and definitive cell types ( Figure S1C ). Progenitors isolated by flow sorting at day 14 possess robust myeloid colony-forming activity, but produce few erythroid or mixed colonies ( Figure 1B ). When cultured in serum-free media with cytokines, they rapidly differentiate and lose this potential, and after 7 days in culture no colonies are ever observed, indicating a complete lack of proliferative and self-renewing potential ( Figure 1B ). We reasoned that if a combination of factors allowed progenitors to proliferate and undergo self-renewal divisions-a basic property of HSCsthese would appear as rare colonies after extended culture. To test the candidate transcription factors in this simple screen, CD34 + CD45 + progenitors were infected with the 9F library, cultured for 7 days, and plated in colony assays. Both CHB6 and MSC-IPS1 progenitors infected with 9F, but not LUC alone, consistently gave rise to colonies in independent experiments ( Figure 1C ). Single colonies were isolated and analyzed for the presence of integrated viral transgenes ( Figure 1D ). The frequency of LUC integrations controlled for infection efficiency, with more frequent integrations being under positive selection. Each colony harbored four to eight integrations, with HLF, ERG, HOXA9, and RORA present in almost every colony. In an independent experiment with a lower transduction efficiency, HOXA9 and RORA were also under selection ( Figure S1D ). The colony-forming capacity could be sustained for at least 3 weeks in culture ( Figure 1E ). To further investigate this renewal potential, we carried out serial replating. Some, but not all, 9F-infected replicates had robust replating potential ( Figure 1F ). Almost all colonies from the replicates with high replating potential had HLF, ERG, HOXA9, and RORA integrations. By contrast, colonies from the poorly replating replicates harbored fewer integrations ( Figure 1G ) suggesting that higher-order combinations were important.
Retrospective analysis has identified HLF, ERG, HOXA9, and RORA as candidate factors that endow embryonic hematopoietic progenitors with self-renewal capacity. To test them prospectively, we infected CD34 + CD45 + cells with all 16 combinations of the four factors and assayed each by plating colonies at day 7 of culture. Rare colonies appeared in single ERGor HOXA9-transduced samples, but both ERG and HOXA9 (abbreviated ''EA'') were required for robust colony-forming activity in both CHB6 and MSC-IPS1 progenitors ( Figures 2A-2C and Figures S2A and S2B ). The addition of RORA (abbreviated ''EAR'') enhanced colony formation, while addition of HLF did not alter the number of colonies for any combination of factors ( Figure 2B ). EA colonies were larger in size, whereas EAR specified more colonies. Consistent with this, EA cultures proliferated more rapidly than EAR, which contained more progenitors with slower cell cycle kinetics (Figures 2D and 2E) . No colonies were observed in any single-infected samples after 14 days of culture. ERG or HOXA9 single-transduced samples also never gave rise to secondary colonies, implying that multiple factors are required for respecification. By contrast, most of the EAR-transduced replicates could be serially replated (Figures 2B, S2A, and S2B) . Based on these data we included RORA in subsequent experiments. Our data suggest that activation of self-renewal in hPSCderived progenitors requires at least two transcription factors-HOXA9 and ERG. Notably, EA also promoted renewal of CB CD34 + progenitors in vitro, and the possibility of respecifying adult progenitors to HSPCs warrants further exploration (Figure S2C) . HOXA9 is the key homeotic gene that defines HSPC identity (Di-Poï et al., 2010; Lawrence et al., 2005) . ERG is a component of HSC renewal during embryogenesis and stress hematopoiesis (Loughran et al., 2008) . ERG is also a transcriptional target of HOXA9, suggesting a basis for their functional cooperation in our assay .
HOXA9, ERG, and RORA Establish a Hematopoietic Hierarchy Individual lineages in the hematopoietic hierarchy can be accurately distinguished by a combination of cell surface antigens. We next examined if EAR-induced hematopoiesis generated progenitor subsets that resemble those found in CB or adult marrow. Cultured EB CD34 + CD45 + progenitors completely differentiate into CD34 À cells after 7 days of culture, which is consistent with loss of clonogenic capacity ( Figure 3A ). By contrast, a CD34 + population was maintained in EAR cultures, expanding between 7 to 14 days, and persisting after that ( Figure 3A ). CD34 + cells were also found in dissociated primary colonies, accounting for serial replating. CD34 expression segregated with the lineage-negative population that did not express myeloid markers CD14, CD15, or CD11b. Human HSCs are found exclusively in the CD34 + CD38 À compartment, and the loss of stem cell potential is correlated with the gradual acquisition of CD38 and loss of CD34 expression (Mazurier et al., 2003) . The starting EBs lack a clearly defined CD34 + CD38 À population ( Figure 3B ). By contrast, EAR established a pattern of CD34 and CD38 closely resembling that of lineage-depleted CB ( Figure 3B ). CD90 + CD49f + cells could be further identified within the CD34 + CD38 À EAR compartment, which is highly enriched for HSCs in CB ( Figure 3B ) (Notta et al., 2011) . Thus, the three factors establish a rudimentary HSPC hierarchy, even in the presence of constitutive transgene expression.
HOXA9, ERG, and RORA Reactivate Expression of HSC Genes
To clarify the molecular basis for self-renewal of respecified progenitors, we performed microarray profiling of CD34 + CD38 À cells isolated by flow sorting from EBs, EAR cultures, and primary CD34 + CD38 À HSCs and CD34 + CD38 + progenitors from CB and fetal liver (FL). Unsupervised clustering showed that these populations segregated to distinct branches, indicating broad differences in gene expression ( Figure 4A ). To define the molecular program initiated by the factors, we identified genes induced or repressed greater than 2-fold by EAR in EB progenitors (t test, FDR < 0.05; Table S1 available online).
The majority of these 2,070 genes were concordantly expressed in HSCs ( Figure 4B ), including genes on in HSCs activated by EAR (group A) and genes off in HSCs repressed by EAR (group C). The transcription factors induced by EAR include RUNX1, HLF, the AP-1 family (FOS, JUN, MAFF) , and GFI1B, all critical elements of a normal HSC program ( Figure 4B ). To analyze this using a different metric, we employed refined signatures for the human HSPC hierarchy (Laurenti et al., 2013) . Six signatures capture the major patterns of early transcription: HSC, MLP (early lymphoid), HSC_MLP (shared stem and lymphoid), GMP (myeloid), CMP_MEP (erythroid), and Progenitor (shared between all progenitors). HSC and HSC_MLP signatures were significantly enriched in EAR compared to EBs ( Figure 4C , bottom row). By contrast, progenitor signatures were enriched in EBs ( Figure 4C , top row). These data show that while factortransduced progenitors retain similarity to EBs, EAR initiates a gene expression program that is shared with normal HSCs.
To further analyze transcriptional changes induced by the three factors, we performed gene-set enrichment analysis for annotated gene sets in the MSigDB database. HSC gene sets and HOXA9 targets were enriched in EAR, while cell cycle, serum response, and oncogene-induced gene sets were enriched in EBs ( Figure S3A ). To test if the factors turn on some HSC-specific genes and repress progenitor-specific genes, we compiled a list of genes differentially expressed between CB/FL HSCs and progenitors (t test, FDR < 0.05; Table S2 ). Genes on in HSCs were largely off in EBs, indicating a loss of stem cell gene expression. EAR activated some of these genes, although the trend did not reach significance ( Figure S3B ). This was mirrored by HSC-specific transcription factors, most of which were underexpressed in EB progenitors ( Figures 4D and 4E) . We discerned two patterns of expression in response to EAR: factors reactivated by EAR to levels similar in HSCs, including HLF, NFIB, HOPX, HMGA2, and RBPMS ( Figure 4D ), and transcription factors not affected by EAR, such as GATA3, Figure S2A ) progenitors using the in vitro colony assay. Independent pluripotent lines are shown to demonstrate reproducibility of the factor combinations. Representative plates for combinations of HOXA9, ERG, and RORA are shown in (A) and (C), and the full quantitation of primary and secondary colonyforming efficiency is shown in (B All data are shown as mean ± SEM of at least three independent replicates. See also Figure S2 .
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, and NKX2-3 ( Figure 4E ). HOXA9 cofactors MEIS1 and PBX1 also belonged to this group. Genes off in HSCs and on in progenitors, including myeloid and erythroid transcription factors, such as GATA1, KLF1, LEF1, CEBPA, and MITF, were highly expressed in EBs and significantly downregulated by EAR ( Figures 4F and S3B ). These data suggest that EB progenitors lack the functional properties of HSCs not only because they fail to upregulate HSC-specific genes, but also because they express negative regulators of stem cell function that define differentiated cells (see Table S3 for EB versus HSC gene list). While respecified progenitors remain different from HSCs (see Table S4 for EAR versus HSC gene list), EAR upregulated a subset of HSC-specific genes and repressed progenitor genes, which likely accounts for their capacity to induce selfrenewal in progenitors.
In Vivo Engraftment Requires SOX4 and MYB We next tested if transcription-factor-respecified progenitors can successfully engraft in irradiated mice. After 2 weeks of primary culture, 1 3 10 6 EAR cells were transplanted into NOD/SCID-IL2Rgnull (NSG) mice. We found no detectable human engraftment 4 weeks after transplant using two independent CD45 antibodies to accurately detect human chimerism (n = 10). This indicated that either EAR was insufficient for even short-term engraftment or that changes induced during culture impaired their capacity for homing and retention in the bone marrow. At the same time, we also transplanted 9F librarytransduced progenitors. One mouse that had received a transplant into the right femur had a 0.2% human engraftment after 4 weeks ( Figure 5A ). The integration pattern in CD45 + cells isolated by flow sorting showed the presence of SOX4 and MYB transgenes in addition to EAR ( Figure 5A ). This finding suggested that different transgenes were selected during in vivo reconstitution and led us to believe that the addition of SOX4 and MYB to our cocktail of transcription factors would enable engraftment of EB-derived progenitors.
Transcription Factors Respecify Myeloid-Restricted Precursors into Multilineage Progenitors
To investigate the functional outcome of combining SOX4 and MYB with HOXA9, ERG, and RORA (EARSM), we infected CD34 + CD45 + progenitors as before and carried out colony assays after 14 days of culture. While EAR gave rise to only myeloid colonies, the addition of SOX4 and MYB prompted the appearance of a large number of blast erythroid (BFU-E) and mixed myelo-erythroid (CFU-GEMM) colonies ( Figure 5B ). Figure 5C ), suggesting that erythroid potential was only realized upon transgene silencing.
To explore this possibility, we switched to an inducible lentiviral system in which rtTA is expressed from the same vector as the transgene (Meerbrey et al., 2011) . Progenitors were infected with five inducible lentiviruses and cultured in doxycycline (Dox) before colonies were plated with or without Dox. As predicted, GEMM colonies formed only upon Dox withdrawal ( Figure 5D ). Colonies plated with Dox contained a mixture of CD11b + cells and CD34
+ self-renewing progenitors; rare erythroid cells were always derived from transgene silencing ( Figure 5E ). Upon Dox withdrawal, CD34 + progenitors differentiated completely into CD235a + CD71
+ erythroid or CD11b + cells ( Figure 5E ). Rapid cessation of self-renewal upon Dox withdrawal is explained by the lack of endogenous HOXA9 and ERG transcription, making the system sensitive to induced transgene expression (Figure S4 ). This presents an attractive system with a high degree of control over self-renewal versus differentiation to model normal and disease hematopoiesis. Two hypotheses can be put forward to account for the appearance of mixed colonies after factor transduction. One possibility is expansion of the rare GEMM progenitors present 
Cell Stem Cell
Respecification of Engraftable Blood Progenitors in the day 14 EBs. Due to heterogeneity among hPSC lines, rare GEMM colonies were in fact detected in MSC-IPS1, but not CHB6 EB progenitors ( Figure 5F ). In stark contrast, the emergence of GEMM colonies after EARSM transduction was efficient (up to 25% of all colonies) and highly reproducible with both CHB6 and MSC-IPS1 lines ( Figure 5F ). We tested the effect of culture on immobilized Delta1, which has been shown to support the expansion of HSPCs by providing a low level Notch signal (Delaney et al., 2005) . Delta1-cultured progenitors trended toward higher numbers of GEMM colonies, but the trend did not reach significance. To examine this further, we screened a panel of IPSC lines and identified two lines, BJ-IPS1 and CD45-IPS1, derived from normal foreskin fibroblasts and CD45 + peripheral blood cells, respectively, that did not give rise to BFU-E or GEMM colonies ( Figure 5F , ''Other IPSCs''). Both lines reproducibly gave rise to erythroid and mixed colonies after induction with EARSM ( Figure 5F ). These data argue against the possibility that the factors simply expand progenitors present in the starting EBs and instead suggest that they actively respecify myeloidrestricted precursors to a myelo-erythroid fate. Lymphoid potential is critical evidence for respecification, since EB progenitors do not generate B or T cells (Martin et al., 2008) . To test lymphoid potential, we seeded EAR-transduced cells on OP9-DL1 stroma that promotes T cell differentiation. CB CD34 + cells progress through well-defined stages of differentiation, starting with the acquisition of early lymphoid markers CD7 and CD5 and culminating with CD4 + CD8 + lymphocytes. We noted that EAR cultures from which Dox was removed failed to proliferate; however, continued exposure to Dox reduced maturation past the CD7 + stage. Cultures in which Dox was added for the first 2 weeks only showed improved maturation, with more than 4% of lymphocytes reaching the CD4 + CD8 + stage after 5 weeks ( Figure 5G ). Similar frequencies of CD1a + and CD3 + cells were observed ( Figure S5 ). By comparison, >13% of CB CD34 + cells were CD4 + CD8 + with robust coexpression of CD1a and CD3 ( Figures 5G and S5 ). These data show that factor-induced progenitors harbor lymphoid potential indicative of respecification to a definitive cell type. However, their lymphoid potential is considerably less than that for adult progenitors, and further optimization of transcription factor combinations is needed.
Respecified Progenitors Mediate Short-Term Myeloid and Erythroid Engraftment
The establishment of a robust and reproducible transplantation model from hPSCs is an important goal. To test the engraftment potential of respecified progenitors, we used the inducible transgene system to expand EB-derived progenitors for 14 days with Dox, and transplanted 0.8-1.2 million cells Figure S3 , Table S3 , and Table S4. (expanded from <5,000 EB CD34 + CD45 + cells) into the femurs of adult NSG mice. Human engraftment was evaluated after 4 or 8 weeks using two human CD45 antibodies, erythroid (CD235a), myeloid (CD33), and lymphoid (CD19, CD5) lineage markers.
Mice transplanted with MSC-IPS1 EARSM progenitors were engrafted in the injected femur after 4 weeks, and at lower levels, in the rest of bone marrow ( Figure 6A and Figure S6A ). We observed only minimal engraftment in mice when Dox was removed ( Figure S6B ). When Dox was administered, almost all injected mice were engrafted, with an average engraftment across several independent experiments and culture conditions of 2.1% (9 of 12 mice engrafted >0.1%). Similar engraftment levels were observed with CHB6-ESC progenitors (average 0.63%, three of four mice engrafted >0.1%) ( Figure 6B ). In most recipients, both myeloid and erythroid cells were present; however, in some mice only myeloid or only erythroid engraftment was found ( Figure 6C ). By contrast with CB-transplanted mice, we did not detect CD19 + B cells. To test the reproducibility of this system using independent IPSC lines, we transplanted EARSM-transduced progenitors derived from BJ-IPS and CD45-IPS lines. We observed a similar myelo-erythroid pattern of engraftment in these mice ( Figure 6D ). In total, 16 of 21 mice transplanted from four hPSC lines were engrafted, with an average engraftment of 2.7% ( Figure 6E ). The presence of erythroid engraftment was notable since immunodeficient mice do not robustly support human erythropoiesis . We observed that several mice with symptoms of radiation sickness-low weight, enlarged spleens, and peripheral lymphocytopenia-had high levels of erythroidonly engraftment, suggesting that intense myeloablation promotes erythropoiesis in this model ( Figure 6C ). Erythroid development in vivo was not inhibited by exposure to Dox possibly due to lower effective levels in tissues. Engraftment levels declined during extended transplantation. Low-level myeloid engraftment persisted 10-12 weeks posttransplant; however, erythroid cells were not detectable beyond 6 weeks ( Figure S6C ). These findings demonstrate that progenitors respecified from multiple hPSC lines mediate reproducible short-term engraftment. To determine the basis for the beneficial effect of SOX4 and MYB on engraftment, we carried out expression profiling of CD34 + CD38
À cells induced with the five factors. These samples clustered closely to EAR, indicating an overall similarity between all respecified progenitors ( Figure S7A ). Gene ontology categories for hematopoietic development and immune function were enriched among genes differentially regulated by EARSM relative to EAR ( Figure S7B ). EAR was associated with aberrant induction of a number of genes, such as heat-shock proteins (HSPA6) and Fcg receptors (FCGR2A, FCGR2B, and FCGR2C) ( Figure S7C ). Repression of these transcripts by SOX4 and MYB may restore engraftment capacity of in vitro-specified cells.
Globin Switching during In Vivo Human Erythropoiesis
A pervasive feature of erythroid differentiation from hPSCs is the retention of embryonic and fetal patterns of globin expression (Chang et al., 2006; Dias et al., 2011) . This property has been reported using independent protocols, suggesting that erythroid precursors fail to receive cues that promote proper developmental maturation reflected by globin gene switching (Anstee et al., 2012) . Consistent with reported findings, BFU-Es isolated from CD34 + CD45 + EBs expressed embryonic ε globin and fetal g globin, but little or no adult b globin ( Figure 7A ). Respecification with EARSM did not alter this pattern of globin expression in vitro ( Figure 7A ). An important question that we sought to address is whether the adult bone marrow microenvironment could provide the cues to alter globin preference. To this end, we analyzed erythroid engraftment in EARSM-transplanted mice. Mouse erythrocytes were gated out with anti-mouse Ter119, showing that the majority of human erythrocytes were CD235a + CD71 + ( Figure 7B ). The marrow of cytopenic mice contained more Ter119 + cells reflective of stress erythropoiesis, accompanied by progressive maturation of human erythrocytes ( Figure 7B ). The majority of sorted human CD235a + CD71 + cells were at the late erythroblast-normoblast stage of differentiation by morphology ( Figure 7C ) and marked by high levels of Band3 and low levels of CD49d ( Figure 7D ). Human erythrocytes do not readily enucleate in vivo; however, we detected some enucleated cells both by morphology and nuclear dye uptake ( Figures 7C and 7D) . Thus, hPSC-derived progenitors undergo erythroid maturation in vivo. We next examined the pattern of hemoglobin expression in CD235a + CD71 + erythroblasts isolated from engrafted mice.
Remarkably, ε globin was suppressed (4.0% of total globin, range 0.9%-7.1%), and b globin (12.6% of total globin, range 3.6%-28.1%) was induced, compared to cultured erythroblasts ( Figure 7E ). As expected, mice engrafted with CB expressed a mixture of g and b globins. These findings were supported by analysis in single sorted CD235a + CD71 + cells. Single CB cells isolated from colonies or engrafted mice almost uniformly coexpressed g and b globins ( Figure 7F) . Remarkably, 41.9% of EARSM-engrafted cells coexpressed g and b globin, and a significant proportion (12.9%) expressed only b globin ( Figure 7F ). By comparison, adult globin-expressing cells were never detected in vitro ( Figure 7F ). The total levels of globin transcripts, and the degree of erythroid maturation as evidenced by Band3 and CD49d, were similar between cells isolated in vitro or in vivo ( Figure 7D ). These findings demonstrate that human IPSC-derived erythroid precursors respecified with transcription factors undergo hemoglobin switching in vivo, giving rise to definitive erythrocytes.
DISCUSSION
Generation of engraftable HSPCs from human pluripotent cells is a major goal in regenerative medicine. Here we report a significant advance toward this goal using a transcription-factormediated approach. In our system hPSCs are differentiated to hematopoietic progenitors and then transduced with a combination of HSC transcription factors that aim to respecify these progenitors to a stem cell fate. Using an in vitro screen to identify relevant combinations of factors, we demonstrate that HOXA9, ERG, and RORA convert myeloid-restricted precursors into self-renewing multilineage HSPCs with erythroid and lymphoid potential. These factors are sufficient to expand progenitors while maintaining a hierarchy with CD34 + CD38 À ''stem cells.'' HOXA9 and ERG can be further modified by SOX4 and MYB to enable short-term myelo-erythroid engraftment. These findings establish a transcription-factor-based system for engraftment from hPSCs that will serve as a platform for further improvements in transplantation potential. The advent of IPSC technology has enabled the generation of pluripotent lines from patients with hematologic diseases. The hope has been that these lines can serve as models to gain insight into the molecular basis of these diseases and as platforms for drug screens (Cherry and Daley, 2013) . However, the inability to generate large numbers of engraftable cells has precluded disease modeling in vivo, thereby limiting the scope of experiments and drug screens that can be performed. Our system described here may be suitable for modeling anemias and other red blood cell disorders due to its ability to generate large numbers of erythroid precursors in vitro, robust erythroid engraftment that can be enhanced by intensive myeloablation, and a high degree of hemoglobin maturation in vivo. Due to the near-unlimited capacity to produce erythroid cells, this transcription factor approach may also be suitable for transfusion-related applications (Migliaccio et al., 2012) .
Erythroid precursors differentiated from hPSCs express embryonic and fetal, but not adult, hemoglobin (Chang et al., 2006) . Induction of a switch to adult globin, critical for modeling thalassemias and sickle cell anemia caused by mutations in the HbB locus, has been the subject of intense investigation. Silencing of embryonic and fetal globins is mediated by BCL11A, in tandem with KLF1, MYB, and others (Sankaran and Orkin, 2013; Sankaran et al., 2009 ). One possibility is that the expression or activity of these factors is not induced during hPSC differentiation in vitro resulting in the persistence of embryonic and fetal globins. The finding that erythrocytes in transplanted mice silence embryonic and induce adult globins supports the long-standing hypothesis that the bone marrow microenvironment can promote globin switching. This raises the possibility that globin switching is initiated by specific signaling pathways that activate BCL11A and other regulators following the migration of HSCs from FL to bone marrow after birth. The nature of these signals remains completely unknown. Since globin switching is regulated in a species-specific manner, transplantation of hPSC progenitors can serve as a model to interrogate the nature of the signaling interactions that drive globin switching (Sankaran et al., 2009) . Transcription factors that control stem cell state act as part of complex gene regulatory networks, and while these networks have been extensively modeled, functional studies have largely focused on the role of individual factors in controlling HSC fate (Orkin and Zon, 2008; Wilson et al., 2010) . The respecification approach presents an opportunity to identify functional networks of cooperating factors. HOXA9 and ERG have been known to be required for HSC specification and expansion (Lawrence et al., 2005; Loughran et al., 2008) . Both factors are also known oncogenes, and it is now well-established that normal selfrenewal programs, if constitutively activated or dysregulated, can promote aberrant expansion of leukemic cells (Eppert et al., 2011 ). Our findings demonstrate that HOXA9, ERG, RORA, SOX4, and MYB are part of the same functional gene regulatory network. HOXA9 occupies ERG, SOX4, and MYB promoters, linking them on a molecular level . We propose that this network may have an important role in adult HSCs and leukemia-initiating cells. Our approach may provide deeper insights into the principles underlying the organization of HSC networks.
Current strategies for deriving HSPCs from heterologous cell types are based on directed differentiation from hPSCs or reprogramming of somatic cells (Pereira et al., 2013) . We propose a hybrid strategy aiming to respecify HSCs from closely related progenitors by activating stem cell gene regulatory networks. However, respecification with our current factors has not achieved the major goal of generating a cell with long-term and multilineage repopulation potential. HSC state is controlled by a large number of transcription factors and epigenetic modifiers (Doulatov et al., 2012; Orkin and Zon, 2008) . Powerful screening strategies are thus needed to identify rare combinations of cooperating factors. Our approach is based on detecting clonogenic progenitors arising as a result of self-renewal divisions in culture. However, these cell states may be incompatible with the in vivo requirements for HSC function. The alternative is to respecify directly in vivo to take advantage of the cues that normally support HSC self-renewal. However, only very rare combinations can likely be detected in this setting. The strategy we describe here provides a logical platform for pursuing both in vitro and in vivo screens aiming to reveal improved sets of factors that extend stem cell properties of respecified progenitors.
EXPERIMENTAL PROCEDURES
Details on colony assays, flow cytometry, microarray profiling, mouse transplantation, assessment of human cell engraftment, and quantitative and single-cell PCR are described in the Supplemental Experimental Procedures available online.
hPSC Culture All experiments were performed with CHB6 ESC (NIH #0006) and MSC-IPS1 (Park et al., 2008) . Human ESCs and IPSCs were maintained on mouse embryonic fibroblasts (GlobalStem) feeders in DMEM/F12 + 20% KnockOutSerum Replacement (Invitrogen), 1 mM L-glutamine, 1 mM NEAA, 0.1 mM b-mercaptoethanol, and 10 ng/ml bFGF. Media was changed daily, and cells were passaged 1:4 onto fresh feeders every 7 days using standard clump passaging with collagenase IV.
EB Differentiation
EB differentiation was performed as previously described (Chadwick et al., 2003) . Briefly, hPSC colonies were scraped into nonadherent rotating 10 cm plates. EB media was KO-DMEM + 20% FBS (Stem Cell Technologies), 1 mM L-glutamine, 1 mM NEAA, penicillin/streptomycin, 0.1 mM b-mercaptoethanol, 200 mg/ml h-transferrin, and 50 mg/ml ascorbic acid. After 24 hr, media was changed by allowing EBs to settle by gravity and replacing with EB media supplemented with growth factors as follows: 50 ng/ml BMP4 (R&D Systems), 300 ng/ml SCF, 300 ng/ml FLT3, 50 ng/ml G-CSF, 20 ng/ml IL-6, 10 ng/ml IL-3 (all Peprotech). Media was changed on day 5 and day 10. EBs were dissociated on day 14 by digestion with collagenase B (Roche) for 2 hr and by treatment with enzyme-free dissociation buffer (GIBCO), then filtered through an 80 mm filter. Dissociated EBs were frozen in 10% DMSO and 40% FBS freezing solution.
Lentivirus Production
Plasmids for the 9F library were obtained as Gateway plasmids (GeneCopoeia). Open reading frames were cloned into lentiviral vectors using LR Clonase (Invitrogen). Two vectors were used, pSMAL-GFP (constitutive) and pINDUCER-21 (Meerbrey et al., 2011) . Lentiviral particles were produced by transfecting 293T-17 cells (ATCC) with the third-generation packaging plasmids. Virus was harvested 12 and 36 hr after transfection and concentrated by ultracentrifugation at 23,000 rpm for 2 hr. Constructs were titered by serial dilution on 293T cells.
Progenitor Sorting
Dissociated EB cells were thawed following the Lonza Poietics protocol (http://bio.lonza.com/uploads/tx_mwaxmarketingmaterial/Lonza_ ManualsProductInstructions_Procedure_for_Thawing_Poietics_Cells.pdf) and resuspended at 1 3 10 6 per 100 ml staining buffer (PBS + 2% FBS). Cells were stained with a 1:50 dilution of CD45 PE-Cy5 (Immu19.2; Clontech), CD34 PE-Cy7 (8G12; BD), and DAPI for 20 min at room temperature. All sorting was performed on a BD FACS Aria II cell sorter using a 70 mm nozzle.
Lentiviral Gene Transfer
Sorted CD34 + CD45 + progenitors were seeded on fibronectin-coated (10 mg/cm 2 ) 96-well plates at a density of 2 to 5 3 10 4 cells per well. The infection media was IMDM + 20% BIT (StemCell Technologies), 1 mM L-glutamine, and 0.1 mM b-mercaptoethanol, with 300 ng/ml SCF, 300 ng/ ml FLT3, 50 ng/ml G-CSF, 20 ng/ml IL6, and 10 ng/ml IL3 (all Peprotech). Lentiviral infections were carried out in a total volume of 150 ml. The multiplicity of infection for the factors was as follows: 9F 20, ERG 5.0, HOXA9 5.0, RORA 3.0, SOX4 3.0, and MYB 3.0. Virus was concentrated onto cells by centrifuging the plate at 2,500 rpm for 30 min at room temperature. Infections were carried out for 24-36 hr.
Progenitor Culture
Following gene transfer, progenitors were cultured in suspension in infection media supplemented with 50 ng/ml SCF, 50 ng/ml FLT3, 50 ng/ml TPO, 50 ng/ml IL6, and 10 ng/ml IL3 (all R&D Systems). To standardize these conditions, for all experiments with inducible constructs (including all transplantation experiments), infection media was replaced with StemSpan SFEM (StemCell Technologies). Dox was added at 2 mg/ml (Sigma). For culturing on immobilized ligands, nontissue culture plates were coated with 2.5 mg/ml Delta1 extIgG and 5 mg/ml recombinant human retronectin (CH296, Takara Bio) for 2 hr at 37 C. Culture media was same as above. Cultures were maintained at a density of <1 3 10 6 cells/ml, and media was changed every 3-4 days.
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